U.K. biotech Complement Therapeutics Ltd (CTx) has come out of stealth mode with €5 million ($5.7 million) in seed funding to tackle complement-related diseases, initially targeting the currently untreatable condition geographic atrophy due to dry age-related macular degeneration. The company, a preclinical spinout from the University of Manchester, has the backing of European venture capital firms Biogeneration Ventures (BGV) and Forbion.